Table 2.

Patient characteristics at baseline

	Number of patients (n = 161; exploration cohort)	Number of patients (n = 161; validation cohort)
Gender
Male	108 (67%)	94 (58%)
Female	53 (33%)	67 (42%)
Age at start (years)
Mean (±SD)	64 (±8.1)	65 (±9.1)
WHO performance status
0	26 (16%)	28 (17%)
1	95 (59%)	93 (58%)
2	2 (1%)	5 (3%)
3	1 (1%)	0 (0%)
Unknown	37 (23%)	35 (22%)
Primary lung tumour
Adenocarcinoma	97 (60%)	101 (63%)
Squamous cell carcinoma	47 (29%)	49 (30%)
Great cell carcinoma	15 (9%)	7 (4%)
Unspecified	2 (1%)	4 (3%)
Number of pre-treatment lines
0	1 (1%)	0 (0%)
1	104 (65%)	113 (70%)
2	44 (27%)	38 (24%)
>2	12 (7%)	10 (6%)
Ethnicity
Caucasian	152 (94%)	156 (97%)
Other	4 (3%)	1 (1%)
Unknown	5 (3%)	4 (3%)